BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 26134262)

  • 21. Present and future molecular testing of lung carcinoma.
    Dacic S; Nikiforova MN
    Adv Anat Pathol; 2014 Mar; 21(2):94-9. PubMed ID: 24508692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
    Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In Vitro Drug Sensitivity Tests to Predict Molecular Target Drug Responses in Surgically Resected Lung Cancer.
    Miyazaki R; Anayama T; Hirohashi K; Okada H; Kume M; Orihashi K
    PLoS One; 2016; 11(4):e0152665. PubMed ID: 27070423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Diagnostic and therapeutic biomarkers for lung cancer patients].
    Seike M; Gemma A
    Nihon Rinsho; 2012 May; 70(5):809-15. PubMed ID: 22620005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.
    Katayama R; Lovly CM; Shaw AT
    Clin Cancer Res; 2015 May; 21(10):2227-35. PubMed ID: 25979929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance.
    Ye M; Zhang X; Li N; Zhang Y; Jing P; Chang N; Wu J; Ren X; Zhang J
    Oncotarget; 2016 Mar; 7(11):12289-304. PubMed ID: 26802023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent progress in systemic treatment for lung cancer.
    Clark JW; Longo DL
    Curr Opin Pulm Med; 2018 Jul; 24(4):355-366. PubMed ID: 29697418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenomic biomarkers for personalized cancer treatment.
    Rodríguez-Antona C; Taron M
    J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive markers in lung cancer: a few hints for the practicing pathologist.
    Barbareschi M; Barberis M; Buttitta F; Doglioni C; Fiorentino M; Fontanini G; Franco R; Marchetti A; Rossi G; Troncone G
    Pathologica; 2018 Mar; 110(1):29-38. PubMed ID: 30259911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemotherapy for lung cancers: here to stay.
    Kris MG; Hellmann MD; Chaft JE
    Am Soc Clin Oncol Educ Book; 2014; ():e375-80. PubMed ID: 24857127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance to molecularly targeted therapy in non-small-cell lung cancer.
    Asao T; Takahashi F; Takahashi K
    Respir Investig; 2019 Jan; 57(1):20-26. PubMed ID: 30293943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
    Rimkunas VM; Crosby KE; Li D; Hu Y; Kelly ME; Gu TL; Mack JS; Silver MR; Zhou X; Haack H
    Clin Cancer Res; 2012 Aug; 18(16):4449-57. PubMed ID: 22661537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy.
    Saito M; Suzuki H; Kono K; Takenoshita S; Kohno T
    Surg Today; 2018 Jan; 48(1):1-8. PubMed ID: 28280984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarkers for personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
    Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
    J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Companion biomarkers: paving the pathway to personalized treatment for cancer.
    Duffy MJ; Crown J
    Clin Chem; 2013 Oct; 59(10):1447-56. PubMed ID: 23656699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biomarkers for ALK and ROS1 in Lung Cancer: Immunohistochemistry and Fluorescent In Situ Hybridization.
    Luk PP; Selinger CI; Mahar A; Cooper WA
    Arch Pathol Lab Med; 2018 Aug; 142(8):922-928. PubMed ID: 29902067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lung adenocarcinoma with concurrent ALK and ROS1 rearrangement: A case report and review of the literatures.
    Deng H; Liu C; Zhang G; Wang X; Liu Y
    Pathol Res Pract; 2018 Dec; 214(12):2103-2105. PubMed ID: 30327151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different histopathology but the same clonality: ALK rearrangement in a patient with metastatic non-small-cell lung cancer.
    Zhao J; Zhou J; Chen Z; Wang B; Zhang X; Zhou J; Ding W
    Int J Clin Exp Pathol; 2015; 8(3):3344-8. PubMed ID: 26045865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.